Literature DB >> 30997845

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Alexandra Gomez-Arteaga1, Elizabeth Margolskee2, Mike T Wei1, Koen van Besien1, Giorgio Inghirami2, Steven Horwitz3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30997845      PMCID： PMC8162842          DOI： 10.1080/10428194.2019.1594220

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  25 in total

1.  How I treat prolymphocytic leukemia.

Authors:  Claire Dearden
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

2.  Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.

Authors:  Lorraine Springuel; Tekla Hornakova; Elisabeth Losdyck; Fanny Lambert; Emilie Leroy; Stefan N Constantinescu; Elisabetta Flex; Marco Tartaglia; Laurent Knoops; Jean-Christophe Renauld
Journal:  Blood       Date:  2014-10-28       Impact factor: 22.113

Review 3.  Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2016-07-26       Impact factor: 7.658

4.  Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

Authors:  R Pawson; M J Dyer; R Barge; E Matutes; P D Thornton; E Emmett; J C Kluin-Nelemans; W E Fibbe; R Willemze; D Catovsky
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

5.  Array-based genomic resequencing of human leukemia.

Authors:  Y Yamashita; J Yuan; I Suetake; H Suzuki; Y Ishikawa; Y L Choi; T Ueno; M Soda; T Hamada; H Haruta; S Takada; Y Miyazaki; H Kiyoi; E Ito; T Naoe; M Tomonaga; M Toyota; S Tajima; A Iwama; H Mano
Journal:  Oncogene       Date:  2010-04-19       Impact factor: 9.867

6.  Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Authors:  M J Keating; B Cazin; S Coutré; R Birhiray; T Kovacsovics; W Langer; B Leber; T Maughan; K Rai; G Tjønnfjord; M Bekradda; M Itzhaki; P Hérait
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

7.  Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.

Authors:  Claude Haan; Catherine Rolvering; Friedrich Raulf; Manuela Kapp; Peter Drückes; Gebhard Thoma; Iris Behrmann; Hans-Günter Zerwes
Journal:  Chem Biol       Date:  2011-03-25

8.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

9.  JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

Authors:  Sandrine Degryse; Charles E de Bock; Luk Cox; Sofie Demeyer; Olga Gielen; Nicole Mentens; Kris Jacobs; Ellen Geerdens; Valentina Gianfelici; Gert Hulselmans; Mark Fiers; Stein Aerts; Jules P Meijerink; Thomas Tousseyn; Jan Cools
Journal:  Blood       Date:  2014-09-05       Impact factor: 22.113

Review 10.  Evolution of the JAK-STAT pathway.

Authors:  Clifford Liongue; Alister C Ward
Journal:  JAKSTAT       Date:  2013-01-01
View more
  14 in total

1.  Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.

Authors:  Hemant S Murthy; Kwang Woo Ahn; Noel Estrada-Merly; Hassan B Alkhateeb; Susan Bal; Mohamed A Kharfan-Dabaja; Bhagirathbhai Dholaria; Francine Foss; Lohith Gowda; Deepa Jagadeesh; Craig Sauter; Muhammad Bilal Abid; Mahmoud Aljurf; Farrukh T Awan; Ulrike Bacher; Sherif M Badawy; Minoo Battiwalla; Chris Bredeson; Jan Cerny; Saurabh Chhabra; Abhinav Deol; Miguel Angel Diaz; Nosha Farhadfar; César Freytes; James Gajewski; Manish J Gandhi; Siddhartha Ganguly; Michael R Grunwald; Joerg Halter; Shahrukh Hashmi; Gerhard C Hildebrandt; Yoshihiro Inamoto; Antonio Martin Jimenez-Jimenez; Matt Kalaycio; Rammurti Kamble; Maxwell M Krem; Hillard M Lazarus; Aleksandr Lazaryan; Joseph Maakaron; Pashna N Munshi; Reinhold Munker; Aziz Nazha; Taiga Nishihori; Olalekan O Oluwole; Guillermo Ortí; Dorothy C Pan; Sagar S Patel; Attaphol Pawarode; David Rizzieri; Nakhle S Saba; Bipin Savani; Sachiko Seo; Celalettin Ustun; Marjolein van der Poel; Leo F Verdonck; John L Wagner; Baldeep Wirk; Betul Oran; Ryotaro Nakamura; Bart Scott; Wael Saber
Journal:  Transplant Cell Ther       Date:  2022-01-23

2.  What factors guide treatment selection in mycosis fungoides and Sezary syndrome?

Authors:  Youn H Kim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.

Authors:  Stephen Dong; Tarek Khedro; Pamela Ward; Louis Dubeau; Bassam Yaghmour; Imran Siddiqi; George Yaghmour
Journal:  Br J Haematol       Date:  2020-07-25       Impact factor: 6.998

4.  An Enteropathy-like Indolent NK-Cell Proliferation Presenting in the Female Genital Tract.

Authors:  Rahul Krishnan; Kari Ring; Eli Williams; Craig Portell; Elaine S Jaffe; Alejandro A Gru
Journal:  Am J Surg Pathol       Date:  2020-04       Impact factor: 6.298

5.  Advances and Perspectives in the Treatment of T-PLL.

Authors:  Till Braun; Jana von Jan; Linus Wahnschaffe; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

6.  JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.

Authors:  Linus Wahnschaffe; Till Braun; Sanna Timonen; Anil K Giri; Alexandra Schrader; Prerana Wagle; Henrikki Almusa; Patricia Johansson; Dorine Bellanger; Cristina López; Claudia Haferlach; Marc-Henri Stern; Jan Dürig; Reiner Siebert; Satu Mustjoki; Tero Aittokallio; Marco Herling
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

Review 7.  T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches.

Authors:  Ana Colon Ramos; Kidist Tarekegn; Amandeep Aujla; Katherine Garcia de de Jesus; Sachin Gupta
Journal:  Cureus       Date:  2021-02-09

Review 8.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

9.  Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias.

Authors:  Linus Wahnschaffe; Marco Herling
Journal:  Hemasphere       Date:  2021-06-01

10.  Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations.

Authors:  Jonathan Wong; Meaghan Wall; Gregory Philip Corboy; Nadine Taubenheim; Gareth Peter Gregory; Stephen Opat; Jake Shortt
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.